Lastly, similar results have recently been reported for gilteritinib, a dual FLT3/AXL inhibitor (with a minimal activity on KIT) approved for the use in relapsed/refractory FLT3-mutated AML. This evidence concerns the gene KIT and acute myeloid leukemia.